Abstract:Portal vein involvement is considered one of the most fearful complications of hepatocellular carcinoma (HCC). Portal vein tumor thrombosis (PVTT) is associated with aggressive tumor biology (high grade), high tumor burden (number and size of lesions), high levels of serum markers (AFP), poor liver function (deranged LFT), and poor performance status of patients. The Barcelona Clinic Liver Cancer staging system places HCC patients with PVTT in advanced stage (BCLC Stage-C). This group contains a fairly heterogeneous patient population, previously considered candidates for palliative systemic therapy with sorafenib. However, this provided modest overall survival (OS) benefit. The results of a recent Phase III (IMbrave150) trial favor the combination of atezolizumab and bevacizumab over sorafenib as a standard of care in advanced unresectable HCC. While only lenvatinib proved to be non-inferior against sorafenib in a phase III (REFLECT trial), regorafenib (RESORCE trial), ramucirumab (REACH-2), and cabozantinib (CELESTIAL) have been approved second-line therapy in phase III clinical trials. Recently, the data on the prospect of other modalities in the management of HCC with PVTT is mounting with favorable results. Targeting multiple pathways in the HCC cascade using a combination of drugs and other modalities such as RT, TACE, TARE, and HAIC appear effective for systemic and loco-regional control. The quest for the ideal combination therapy and the sequence set is still widely unanswered and prospective trials are lacking. With the armament of available therapeutic options and the advances and refinements in the delivery system, down-staging patients to make them eligible for curative resection has been reported. In a rapidly evolving treatment landscape, performing surgery when appropriate, in the form of LR and even LT to achieve cure does not seem farfetched. Likewise, adjuvant therapy and prompt management of the recurrences holds the key to prolong OS and DFS. This review discusses the management options of HCC patients with PVTT.

A new and rare type of hepatocellular carcinoma: survival and gene analysis of portal vein tumour thrombus-type hepatocellular carcinoma

Proteomics Analysis of Distinct Portal Vein Tumor Thrombi in Hepatocellular Carcinoma Patients

Clinicopathologic characteristics and surgical outcomes of hepatocellular carcinoma with portal vein tumor thrombosis.

A new classification for hepatocellular carcinoma with portal vein tumor thrombus

Portal vein tumor thrombosis in hepatocellular carcinoma: molecular mechanism and therapy

Progress on the molecular mechanism of portal vein tumor thrombosis formation in hepatocellular carcinoma

Foxp3+ Regulatoryt Cells and the Formation of Portal Vein Tumour Thrombus in Patients with Hepatocellular Carcinoma

Portal Vein Tumor Thrombus is a Bottleneck in the Treatment of Hepatocellular Carcinoma

Identification of Portal Vein Tumor Thrombus with an Independent Clonal Origin in Hepatocellular Carcinoma Via Multi-Omics Data Analysis

Actual long-term survival in HCC patients with portal vein tumor thrombus after liver resection: a nationwide study

Multimodality Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

The Prognostic Comparison Between Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and Bile Duct Cancer Thrombus After Liver Resection

The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma - The Changing Tides

Clinical Analysis of hepatocellular carcinoma patients with segmental portal vein tumor thrombus after deceased donor liver transplantation: a long-term retrospective study

A Retrospective Study on Two Surgical Techniques in the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and to Determine the Prognostic Factors of Overall Survival

A New Staging System for Hepatocellular Carcinoma Associated with Portal Vein Tumor Thrombus

Hepatocellular carcinoma with tumor thrombi in the portal vein. A comparison of therapeutic effects by different treatments]

Prognostic Analysis for Treatment Modalities in Hepatocellular Carcinomas with Portal Vein Tumor Thrombi.

A new classification for hepatocellular carcinoma with hepatic vein tumor thrombus

Comparison of Liver Transplantation and Liver Resection for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus Type I and Type II